CA2805505C - Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof - Google Patents
Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof Download PDFInfo
- Publication number
- CA2805505C CA2805505C CA2805505A CA2805505A CA2805505C CA 2805505 C CA2805505 C CA 2805505C CA 2805505 A CA2805505 A CA 2805505A CA 2805505 A CA2805505 A CA 2805505A CA 2805505 C CA2805505 C CA 2805505C
- Authority
- CA
- Canada
- Prior art keywords
- influenza virus
- gene segment
- virus gene
- type
- coding region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 1437
- 230000002829 reductive effect Effects 0.000 title claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 1251
- 108091026890 Coding region Proteins 0.000 claims abstract description 409
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 315
- 241000700605 Viruses Species 0.000 claims abstract description 251
- 238000004806 packaging method and process Methods 0.000 claims abstract description 116
- 201000010099 disease Diseases 0.000 claims abstract description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 59
- 239000002773 nucleotide Substances 0.000 claims description 699
- 125000003729 nucleotide group Chemical group 0.000 claims description 697
- 108091092724 Noncoding DNA Proteins 0.000 claims description 238
- 101710154606 Hemagglutinin Proteins 0.000 claims description 102
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 102
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 102
- 101710176177 Protein A56 Proteins 0.000 claims description 102
- 239000000185 hemagglutinin Substances 0.000 claims description 99
- 108091081024 Start codon Proteins 0.000 claims description 63
- 101710102873 Polymerase basic protein 2 Proteins 0.000 claims description 57
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims description 57
- 108010006232 Neuraminidase Proteins 0.000 claims description 53
- 102000005348 Neuraminidase Human genes 0.000 claims description 53
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 51
- 230000009385 viral infection Effects 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 31
- 230000037432 silent mutation Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 129
- 150000007523 nucleic acids Chemical group 0.000 abstract description 109
- 230000002265 prevention Effects 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 7
- 101000773184 Homo sapiens Twist-related protein 1 Proteins 0.000 description 150
- 102100030398 Twist-related protein 1 Human genes 0.000 description 150
- 206010022000 influenza Diseases 0.000 description 149
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 114
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 114
- 230000035772 mutation Effects 0.000 description 71
- 108091028043 Nucleic acid sequence Proteins 0.000 description 63
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 description 60
- 101000944174 Homo sapiens Histone acetyltransferase KAT6B Proteins 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 59
- 108700029658 influenza virus NS Proteins 0.000 description 57
- 102100037516 Protein polybromo-1 Human genes 0.000 description 55
- 230000000295 complement effect Effects 0.000 description 47
- 230000009467 reduction Effects 0.000 description 44
- 239000000427 antigen Substances 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 102000036639 antigens Human genes 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 36
- 108020004707 nucleic acids Proteins 0.000 description 36
- 238000002560 therapeutic procedure Methods 0.000 description 36
- 241000712431 Influenza A virus Species 0.000 description 34
- 108091008146 restriction endonucleases Proteins 0.000 description 26
- 241000713297 Influenza C virus Species 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 24
- 241000713196 Influenza B virus Species 0.000 description 22
- 208000037797 influenza A Diseases 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 20
- 235000013601 eggs Nutrition 0.000 description 18
- -1 for example Substances 0.000 description 18
- 101000787132 Acidithiobacillus ferridurans Uncharacterized 8.2 kDa protein in mobL 3'region Proteins 0.000 description 16
- 101000827262 Acidithiobacillus ferrooxidans Uncharacterized 18.9 kDa protein in mobE 3'region Proteins 0.000 description 16
- 101000811747 Antithamnion sp. UPF0051 protein in atpA 3'region Proteins 0.000 description 16
- 101000827607 Bacillus phage SPP1 Uncharacterized 8.5 kDa protein in GP2-GP6 intergenic region Proteins 0.000 description 16
- 101000961975 Bacillus thuringiensis Uncharacterized 13.4 kDa protein Proteins 0.000 description 16
- 101000964407 Caldicellulosiruptor saccharolyticus Uncharacterized 10.7 kDa protein in xynB 3'region Proteins 0.000 description 16
- 101000768777 Haloferax lucentense (strain DSM 14919 / JCM 9276 / NCIMB 13854 / Aa 2.2) Uncharacterized 50.6 kDa protein in the 5'region of gyrA and gyrB Proteins 0.000 description 16
- 101000607404 Infectious laryngotracheitis virus (strain Thorne V882) Protein UL24 homolog Proteins 0.000 description 16
- 101000735632 Klebsiella pneumoniae Uncharacterized 8.8 kDa protein in aacA4 3'region Proteins 0.000 description 16
- 101000818100 Spirochaeta aurantia Uncharacterized 12.7 kDa protein in trpE 5'region Proteins 0.000 description 16
- 101001037658 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Glucokinase Proteins 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 241000282898 Sus scrofa Species 0.000 description 15
- 208000037798 influenza B Diseases 0.000 description 15
- 101150039660 HA gene Proteins 0.000 description 14
- 101710126256 Hydrolase in agr operon Proteins 0.000 description 14
- 238000013519 translation Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000014150 Interferons Human genes 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 230000001932 seasonal effect Effects 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 241001500351 Influenzavirus A Species 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 208000003322 Coinfection Diseases 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000012707 chemical precursor Substances 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 5
- 101710128560 Initiator protein NS1 Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710144127 Non-structural protein 1 Proteins 0.000 description 5
- 102000017143 RNA Polymerase I Human genes 0.000 description 5
- 108010013845 RNA Polymerase I Proteins 0.000 description 5
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 4
- 101150118742 NP gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091034135 Vault RNA Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000711573 Coronaviridae Species 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101150080862 NA gene Proteins 0.000 description 3
- 101150105115 PA gene Proteins 0.000 description 3
- 102000009572 RNA Polymerase II Human genes 0.000 description 3
- 108010009460 RNA Polymerase II Proteins 0.000 description 3
- 241001068263 Replication competent viruses Species 0.000 description 3
- 241000831652 Salinivibrio sharmensis Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- MYYARUCLXARAEE-ZATZPJRKSA-N alpha-C-GalCer Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCCCCC MYYARUCLXARAEE-ZATZPJRKSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229960001226 live attenuated influenza Drugs 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000342334 Human metapneumovirus Species 0.000 description 2
- 241000491226 Influenza A virus (A/WSN/1933(H1N1)) Species 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000144128 Lichtheimia corymbifera Species 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 101710144128 Non-structural protein 2 Proteins 0.000 description 2
- 101710199667 Nuclear export protein Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 108700015453 influenza virus PB2 Proteins 0.000 description 2
- 108010064513 influenza virus polymerase basic protein 1 Proteins 0.000 description 2
- 108700010900 influenza virus proteins Proteins 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- PUMZXCBVHLCWQG-UHFFFAOYSA-N 1-(4-Hydroxyphenyl)-2-aminoethanol hydrochloride Chemical compound [Cl-].[NH3+]CC(O)C1=CC=C(O)C=C1 PUMZXCBVHLCWQG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 1
- 241001664176 Alpharetrovirus Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 241000589944 Aquaspirillum Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000701802 Aviadenovirus Species 0.000 description 1
- 241001519465 Avian metapneumovirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 241000589941 Azospirillum Species 0.000 description 1
- 241000589154 Azotobacter group Species 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241001480523 Basidiobolus ranarum Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000604933 Bdellovibrio Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001231757 Betaretrovirus Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000272161 Charadriiformes Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 241001480517 Conidiobolus Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000235555 Cunninghamella Species 0.000 description 1
- 241000702662 Cypovirus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000031711 Cytophagaceae Species 0.000 description 1
- 241000712467 Cytorhabdovirus Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000222175 Diutina rugosa Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000607473 Edwardsiella <enterobacteria> Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000700572 Entomopoxvirinae Species 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001455610 Ephemerovirus Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000702658 Fijivirus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000588731 Hafnia Species 0.000 description 1
- 241000205035 Halobacteriaceae Species 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241000893570 Hendra henipavirus Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709715 Hepatovirus Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 229940124873 Influenza virus vaccine Drugs 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 241000555269 Ippy mammarenavirus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001494920 Larus argentatus Species 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000714210 Leviviridae Species 0.000 description 1
- 241000714216 Levivirus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000589330 Methylococcaceae Species 0.000 description 1
- 241000700559 Molluscipoxvirus Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282331 Mustelidae Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 101150076514 NS gene Proteins 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000605012 Oceanospirillum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233654 Oomycetes Species 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000702633 Oryzavirus Species 0.000 description 1
- 101150103639 PB1 gene Proteins 0.000 description 1
- 101150030427 PB2 gene Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 241000334993 Parma Species 0.000 description 1
- 241000606752 Pasteurellaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000702656 Phytoreovirus Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108010015329 Respiratory syncytial virus G glycoprotein Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000293824 Rhinosporidium seeberi Species 0.000 description 1
- 241001633102 Rhizobiaceae Species 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000593344 Rhizopus microsporus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000223598 Scedosporium boydii Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241001568331 Vampirovibrio Species 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 108091029474 Y RNA Proteins 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FRGKKTITADJNOE-UHFFFAOYSA-N sulfanyloxyethane Chemical compound CCOS FRGKKTITADJNOE-UHFFFAOYSA-N 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16261—Methods of inactivation or attenuation
- C12N2760/16262—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22985809P | 2009-07-30 | 2009-07-30 | |
| US61/229,858 | 2009-07-30 | ||
| PCT/US2010/043697 WO2011014645A1 (en) | 2009-07-30 | 2010-07-29 | Influenza viruses and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2805505A1 CA2805505A1 (en) | 2011-02-03 |
| CA2805505C true CA2805505C (en) | 2021-08-03 |
Family
ID=42937563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2805505A Active CA2805505C (en) | 2009-07-30 | 2010-07-29 | Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8828406B2 (enExample) |
| EP (1) | EP2459585B1 (enExample) |
| JP (1) | JP5845180B2 (enExample) |
| CA (1) | CA2805505C (enExample) |
| WO (1) | WO2011014645A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| EP2435475B1 (en) | 2009-05-26 | 2018-10-17 | Icahn School of Medicine at Mount Sinai | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
| AU2011217903B2 (en) * | 2010-02-18 | 2017-03-02 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| US9708373B2 (en) | 2010-03-30 | 2017-07-18 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccine and uses thereof |
| US20130189303A1 (en) * | 2011-08-02 | 2013-07-25 | Yan Zhou | Recombinant swine influenza virus and uses thereof |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| WO2013030176A2 (en) * | 2011-09-02 | 2013-03-07 | Westfälische Wilhelms-Universität Münster | Live attenuated influenza virus |
| JP6498439B2 (ja) | 2011-09-20 | 2019-04-17 | アイカーン スクール オブ メディシン アット マウント サイナイ | インフルエンザウイルスワクチン及びその使用 |
| US9371366B2 (en) | 2012-12-18 | 2016-06-21 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| WO2015002978A2 (en) * | 2013-07-02 | 2015-01-08 | The Trustees Of The University Of Pennsylvania | Methods for rapid ribonucleic acid fluorescence in situ hybridization |
| WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| RU2628690C2 (ru) * | 2015-11-06 | 2017-08-21 | Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' | Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| WO2017147486A1 (en) | 2016-02-26 | 2017-08-31 | Alere San Diego Inc. | Redox labeled oligonucleotide probes and their use |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| US11596683B2 (en) | 2016-07-12 | 2023-03-07 | Duke University | Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same |
| EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| US12419946B2 (en) | 2019-02-07 | 2025-09-23 | Duke University | Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same |
| JP7662157B2 (ja) | 2019-02-08 | 2025-04-15 | ウィスコンシン アルムニ リサーチ ファンデイション | ヒト化細胞系 |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| WO2020264141A1 (en) * | 2019-06-26 | 2020-12-30 | Icahn School Of Medicine At Mount Sinai | Influenza virus neuraminidase and uses thereof |
| JP7627911B2 (ja) | 2019-08-27 | 2025-02-07 | ウィスコンシン アルムニ リサーチ ファンデイション | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス |
| US11739303B2 (en) | 2020-01-24 | 2023-08-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized NA |
| WO2021195410A1 (en) * | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022087127A1 (en) * | 2020-10-20 | 2022-04-28 | Duke University | Replication incompetent influenza vaccine platform for foreign protein delivery |
| CN113073115B (zh) * | 2021-06-08 | 2021-10-01 | 北京溯本源和生物科技有限公司 | 一种包装重组流感病毒的重组载体和重组流感病毒及其构建方法和应用 |
| CN115724920A (zh) * | 2021-12-31 | 2023-03-03 | 中国人民解放军军事科学院军事医学研究院 | 冠状病毒和流感病毒的二联核酸疫苗 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US20060019350A1 (en) * | 1989-08-28 | 2006-01-26 | Peter Palese | Recombinant negative strand RNA virus expression system and vacccines |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US6022726A (en) * | 1992-02-03 | 2000-02-08 | Palese; Peter | Genetically engineered attenuated viruses |
| WO1993025788A1 (en) | 1992-06-09 | 1993-12-23 | Hoppe Ag | Latch and lockset system |
| DE69532369T3 (de) | 1994-07-18 | 2010-11-04 | Conzelmann, Karl-Klaus, Prof. Dr. | Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| DE69510207T3 (de) | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
| WO1997012032A1 (en) | 1995-09-27 | 1997-04-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of infectious respiratory syncytial virus from cloned nucleotide sequences |
| EP2112220A3 (en) | 1996-07-15 | 2010-01-06 | The Government of the United States of America, as represented by The Department of Health and Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| KR20000048628A (ko) | 1996-09-27 | 2000-07-25 | 윌리암 에이취 캘넌, 에곤 이 버그 | 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7797798A (en) | 1997-05-23 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
| WO1999002657A1 (en) | 1997-07-11 | 1999-01-21 | Yale University | Rhabdoviruses with reengineered coats |
| CA2302867A1 (en) | 1997-09-19 | 1999-04-01 | American Cyanamid Company | Attenuated respiratory syncytial viruses |
| EP1098961B1 (en) | 1998-06-12 | 2008-01-16 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
| SK288544B6 (sk) | 1998-06-12 | 2018-03-05 | Mount Sinai School Of Medicine | Geneticky skonštruovaný oslabený chimérny vírus chrípky, vakcinačný prostriedok a farmaceutický prostriedok s jeho obsahom a ich použitie |
| US6544785B1 (en) * | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| US6146642A (en) * | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| US8715940B2 (en) * | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
| WO2001004333A1 (en) | 1999-07-14 | 2001-01-18 | Mount Sinai School Of Medicine Of New York University | In vitro reconstitution of segmented negative-strand rna viruses |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| EP2085468A1 (en) | 2000-04-28 | 2009-08-05 | St. Jude Children's Research Hospital | DNA transfection system for the generation of infectious influenza virus |
| JP4430942B2 (ja) * | 2002-02-13 | 2010-03-10 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | インフルエンザウイルスベクターのパッケージングのためのシグナル |
| WO2007044024A2 (en) * | 2004-11-19 | 2007-04-19 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with tandem transcription units |
| US8137676B2 (en) * | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
| HUE037460T2 (hu) * | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
-
2010
- 2010-07-29 WO PCT/US2010/043697 patent/WO2011014645A1/en not_active Ceased
- 2010-07-29 EP EP10748161.6A patent/EP2459585B1/en active Active
- 2010-07-29 US US13/387,485 patent/US8828406B2/en active Active
- 2010-07-29 CA CA2805505A patent/CA2805505C/en active Active
- 2010-07-29 JP JP2012523037A patent/JP5845180B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8828406B2 (en) | 2014-09-09 |
| CA2805505A1 (en) | 2011-02-03 |
| JP5845180B2 (ja) | 2016-01-20 |
| EP2459585A1 (en) | 2012-06-06 |
| EP2459585B1 (en) | 2024-09-04 |
| US20120244183A1 (en) | 2012-09-27 |
| JP2013500720A (ja) | 2013-01-10 |
| WO2011014645A1 (en) | 2011-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2805505C (en) | Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof | |
| US9217157B2 (en) | Recombinant influenza viruses and uses thereof | |
| EP2251034B1 (en) | Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof | |
| US12233123B2 (en) | Influenza virus hemagglutinin proteins and uses thereof | |
| US12364746B2 (en) | Mosaic influenza virus hemagglutinin polypeptides and uses thereof | |
| US9849172B2 (en) | Influenza virus vaccines and uses thereof | |
| JP2013526849A (ja) | インフルエンザウイルスワクチン及びその使用 | |
| HK1178816A (en) | Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof | |
| HK1148957A (en) | Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150728 |